3 years ago

Grey Wolf Therapeutics Secures $49 Million to Advance Novel Anti-Cancer Treatment

  • Oxford-based biotech startup Grey Wolf Therapeutics has raised $49 million in a Series A funding round co-led by Pfizer Ventures and Earlybird Venture Capital

  • The company will use the funds to advance its novel anti-cancer treatment into clinical trials and further develop its pipeline of first-of-their-kind therapeutics

  • Grey Wolf Therapeutics specializes in combating tumors with its immuno-oncology therapeutic technology.

      • ProblemHealthcare

      "Current immune-oncology therapies are limited by poor tumour visibility and T cell exhaustion."

      Solution

      "Grey Wolf Therapeutics is developing a novel anti-cancer treatment that targets these limitations by inhibiting ERAP, a protein that plays a role in both tumour visibility and T cell exhaustion."

      Covered on